| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 302 | 2022 |
| Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies M Lambertini, L Santoro, L Del Mastro, B Nguyen, L Livraghi, D Ugolini, ... Cancer treatment reviews 49, 65-76, 2016 | 288 | 2016 |
| Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer KH Stopsack, S Nandakumar, AG Wibmer, S Haywood, ES Weg, ... Clinical Cancer Research 26 (13), 3230-3238, 2020 | 129 | 2020 |
| Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations JM Mota, E Barnett, JT Nauseef, B Nguyen, KH Stopsack, A Wibmer, ... JCO precision oncology 4, 355-366, 2020 | 113 | 2020 |
| Genomic aberrations in young and elderly breast cancer patients HA Azim, B Nguyen, S Brohée, G Zoppoli, C Sotiriou BMC medicine 13, 1-7, 2015 | 106 | 2015 |
| The underlying tumor genomics of predominant histologic subtypes in lung adenocarcinoma R Caso, F Sanchez-Vega, KS Tan, B Mastrogiacomo, J Zhou, GD Jones, ... Journal of Thoracic Oncology 15 (12), 1844-1856, 2020 | 104 | 2020 |
| Therapeutic implications of germline testing in patients with advanced cancers ZK Stadler, A Maio, D Chakravarty, Y Kemel, M Sheehan, E Salo-Mullen, ... Journal of Clinical Oncology 39 (24), 2698, 2021 | 97 | 2021 |
| Genetic determinants of outcome in intrahepatic cholangiocarcinoma T Boerner, E Drill, LM Pak, B Nguyen, CS Sigel, A Doussot, P Shin, ... Hepatology 74 (3), 1429-1444, 2021 | 94 | 2021 |
| Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics B Nguyen, JM Mota, S Nandakumar, KH Stopsack, E Weg, D Rathkopf, ... European urology 78 (5), 671-679, 2020 | 88 | 2020 |
| Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells C Gómez-Aleza, B Nguyen, G Yoldi, M Ciscar, A Barranco, ... Nature communications 11 (1), 6335, 2020 | 63 | 2020 |
| Inherited TP53 variants and risk of prostate cancer KN Maxwell, HH Cheng, J Powers, R Gulati, EM Ledet, C Morrison, A Le, ... European urology 81 (3), 243-250, 2022 | 56 | 2022 |
| Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry LM Smyth, Q Zhou, B Nguyen, C Yu, EM Lepisto, M Arnedos, MJ Hasset, ... Cancer discovery 10 (4), 526-535, 2020 | 43 | 2020 |
| Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer I Nederlof, D De Bortoli, Y Bareche, B Nguyen, M De Maaker, GKJ Hooijer, ... Breast cancer research 21, 1-13, 2019 | 43 | 2019 |
| Genomic landscape of endometrial carcinomas of no specific molecular profile A Momeni-Boroujeni, B Nguyen, CM Vanderbilt, M Ladanyi, ... Modern Pathology 35 (9), 1269-1278, 2022 | 37 | 2022 |
| Ovarian function and fertility preservation in breast cancer: should gonadotropin-releasing hormone agonist be administered to all premenopausal patients receiving chemotherapy? M Lambertini, F Richard, B Nguyen, G Viglietti, C Villarreal-Garza Clinical Medicine Insights: Reproductive Health 13, 1179558119828393, 2019 | 34 | 2019 |
| Differences in prostate cancer genomes by self-reported race: contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors KH Stopsack, S Nandakumar, K Arora, B Nguyen, SE Vasselman, B Nweji, ... Clinical Cancer Research 28 (2), 318-326, 2022 | 32 | 2022 |
| Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations B Nguyen, D Venet, HA Azim Jr, D Brown, C Desmedt, M Lambertini, ... NPJ Breast Cancer 4 (1), 23, 2018 | 32 | 2018 |
| Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer B Nguyen, D Venet, M Lambertini, C Desmedt, R Salgado, HM Horlings, ... Breast Cancer Research 21, 1-10, 2019 | 28 | 2019 |
| A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial … KL Jhaveri, R Jeselsohn, E Lim, EP Hamilton, K Yonemori, JT Beck, ... Journal of Clinical Oncology 40 (16_suppl), 1021-1021, 2022 | 23 | 2022 |
| Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer B Nguyen, I Veys, S Leduc, Y Bareche, S Majjaj, DN Brown, B Boeckx, ... JNCI: Journal of the National Cancer Institute 111 (7), 742-746, 2019 | 21 | 2019 |
Christos SotiriouUniversité Libre de BruxellesVerified email at bordet.be
